ANP Share Price History
26 Nov, 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
11 Jun, 2020
Antisense Therapeutics Announces a Poster Presentation on the Muscular Dystrophy Association Virtual Conference 2020 website
Antisense Therapeutics (ASX:ANP | US OTC:ATHJY), an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases announces a virtual poster presentation on the Muscular Dystrophy Association (MDA) Virtual 2020 Conference website.
28 May, 2020
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
21 May, 2020
Antisense ATL1102 Final Phase II DMD Results Meet Primary Endpoint and Exceed Expectations on Secondary Endpoints
Antisense Therapeutics ("ANP" or the "Company" ASX:ANP | US OTC:ATHJY) is pleased to advise that the Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) has met its primary endpoint confirming the safety and tolerability of ATL1102 for advancement into a potentially pivotal Phase IIb clinical trial.